Evaluation of tumor localization of In-111 labeled bevacizumab and possible correlation with VEGF expression in patients with colorectal liver metastases.
ID
Source
Brief title
Condition
- Metastases
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
Correlation of In-111 labeled bevacizumab and histological VEGF expression.
Secondary outcome
Not applicable.
Background summary
Variable response to angiogenesis inhibitors; the need of a non-invasive way of
selecting patients for this treatment.
Study objective
Evaluation of tumor localization of In-111 labeled bevacizumab and possible
correlation with VEGF expression in patients with colorectal liver metastases.
Study design
Administration of In-111 labeled bevacizumab, followed by 2 total body scans.
After resection the tumor will be analyzed immunohistochemically.
Study burden and risks
Small risk of side effects of bevacizumab. Burden: 2 hospital visits of 3-4
hours each.
Geert Grooteplein 10
6500 HB Nijmegen
Nederland
Geert Grooteplein 10
6500 HB Nijmegen
Nederland
Listed location countries
Age
Inclusion criteria
Colorectal liver metastases, planned surgical resection within 6 weeks.
Exclusion criteria
Pregnancy, lactation, recent chemotherapy (within 3 months after last chemotherapy regimen).
Design
Recruitment
Medical products/devices used
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| EudraCT | EUCTR2006-002044-29-NL |
| CCMO | NL12163.091.06 |